Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Telles was a joint venture between Metabolix and Archer Daniels Midland (ADM) focused on the commercialization of polyhydroxyalkanoate (PHA) bioplastics under the brand name Mirel. The company utilized microbial fermentation to produce bio-based, biodegradable polymers from renewable resources like corn sugar. While primarily focused on industrial and consumer packaging, Telles' PHA technology had significant applications in the life sciences, including the development of resorbable surgical sutures, medical implants, and controlled-release drug delivery systems. The joint venture was terminated in 2012 when ADM withdrew from the partnership, leading Metabolix to pivot its strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Telles.